Analyst picks & changes

Amgen Inc.


Business: Biopharmaceuticals

AMGN's licensing deal for rights to Novo Nordisk's version of thrombopoietin strengthens the Thousand Oaks, Calif., company's patent position if and when it meets

Genentech Inc.

in patent court over rights to

Read the full 386 word article

How to gain access

Continue reading with a
two-week free trial.